Conversation with The Cancer Letter FDA spells out new systematic approach to giving out–and taking away–accelerated approvals in oncology September 23, 2022Vol.48 No.34By Paul Goldberg
Drugs & Targets FDA approves Retevmo for locally advanced or metastatic RET fusion-positive solid tumors, NSCLC September 23, 2022Vol.48 No.34
Drugs & Targets FDA approves Pedmark to reduce the risk of ototoxicity associated with cisplatin for localized pediatric solid tumors September 23, 2022Vol.48 No.34
Drugs & Targets FDA issues safety alert for squamous cell carcinoma and various lymphomas in scar tissue around breast implants September 16, 2022Vol.48 No.33
Drugs & Targets FDA issues revised draft guidance on charging for investigational drugs under an IND application September 09, 2022Vol.48 No.32
Drugs & Targets FDA accepts ImmunityBio’s BLA for bladder cancer therapy N-803 July 29, 2022Vol.48 No.30
Drugs & Targets FDA grants eltanexor with fast track designation; EU Commission designates eltanexor as an orphan medicinal product July 22, 2022Vol.48 No.29
Drugs & Targets FDA accepts BLA for mosunetuzumab in relapsed or refractory follicular lymphoma July 08, 2022Vol.48 No.27
Drugs & TargetsFree FDA approves Breyanzi in relapsed or refractory large B-cell lymphoma after one prior therapy July 01, 2022Vol.48 No.26
Drugs & TargetsFree FDA issues draft guidance on patient-focused drug development July 01, 2022Vol.48 No.26
